Human Growth Hormone Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2024 - 2030)

Human Growth Hormone Market Drivers & Growth Opportunities

High Incidence of Hyposomatotropism Drives Market Growth

• The biggest driver for the market is the high incidence of hyposomatotropism, or growth hormone deficiency.
• Studies estimate its incidence at 1 in every 4,000 people. This condition can present both during childhood and adulthood and can be both genetic and acquired.
• Further, in many cases, the exact cause is not known, meaning it is idiopathic.
• Key causes include damage to the pituitary gland due to injury or disease, cranial radiation as a treatment for cancer, and chronic kidney diseases (especially in children).
• While in children, human growth hormone deficiency causes stunted growth, in adults, it raises the risk of heart diseases and osteoporosis.
• Synthetic growth hormone is used to manage these conditions in both children and adults.
• Other diseases and disorders this therapy are prescribed for include Turner syndrome (partially or completely missing X chromosome in females), Prader–Willi syndrome (symptomized by low sex hormone levels and poor muscle tone), short bowel syndrome (inadequate nutrient absorption due to disease or surgical removal of a large part of the colon), and muscle wasting disease secondary to HIV.

High Revenue Generation Opportunities in Emerging Economies

• Due to the increasing compliance for the treatments of growth-hormone-related disorders and a big untapped market in developing nations, such as India and China, the global human growth hormone market is predicted to grow.
• Because of their vast populations, India and China are likely to become key opportunistic areas for the healthcare industry in the coming years.
• As a result, drug companies are spending extensively in these countries, which is projected to lead to an increase in growth hormone production.
• The market may need to expand dramatically, which presents chances for investors who want to invest in production platforms in emerging nations to obtain scale, which will ultimately enhance the sale of this drug.

HGH Abuse and Off-Label Could Use Hamper Market Growth

• The key restraint for the human growth hormone market is the increasing abuse of this drug and its off-label abuse.
• The most-common off-label use is sports, as a performance and strength enhancer along with steroids and other agents.
• Although its effect on athletic performance is not known, the World Anti-Doping Agency (WADA) prohibits its usage across all categories of sports.
• Another common user group who regularly abuses HGH is people looking to reverse the natural aging process.
• It is also used to enhance sexual performance, which is another application not approved by the FDA.
• The primary concerns that arise with this non-prescription usage is of higher levels of this hormone, which can have a range of side-effects.
• Common ones include carpel tunnel syndrome, type 2 diabetes (increased insulin resistance), edema in the legs and arms, pain in the joints and muscles, gynecomastia (breast tissue enlargement) in males, and high risk of certain cancers.

Human Growth Hormone Market Analysis

Product Type Insights

The short-acting category is the larger, with a share of 65% in 2024. The use cases of SAGHs are well-established, and this variant has been known for a longer time than its long-acting counterpart. Moreover, acting over short durations, this variant needs to be administered more frequently, which makes is a more-repetitive purchase. Additionally, more patented and generic variants of SAGHs are available compared to LAGHs.

LAGHs will account for the higher CAGR, of 15.5%, during 2024–2030. In many countries, daily recombinant HGH is currently approved for adults and children with a growth hormone deficiency, as it has few side-effects. Daily injections, on the other hand, can be uncomfortable and stressful for certain patients, thus leading to non-adherence and poor treatment results. This has led to the development of a number of LAGH therapies, which allow for a lower injection frequency, such as weekly, bi-weekly, or monthly. These analogs could potentially improve patient acceptance, tolerance, and treatment versatility; thus, they will be preferred in the long run.

The following product types have been analyzed:

• Short-Acting (Larger Category)
• Long-Acting (Faster-Growing Category)

Indication Insights

Turner syndrome accounts for the major market share, of 40%, in 2024. Turner syndrome is a female-specific chromosomal disease characterized by the deletion of one of the X chromosomes, either partially or completely. Symptoms include a receding or indistinct hairline and a wide neck, as well as a high blood pressure, mild eye difficulties, sagging eyelids, and an underactive thyroid gland. Turner syndrome affects about 1 in every 2,000–2,500 newly born females. It is estimated to influence around 70,000 females in the U.S.

Turner syndrome patients are more likely to contract the COVID-19 virus, which can cause serious sickness. They are also more likely to have congenital heart problems, such as a bicuspid aortic valve. Further, COVID-19 can cause significant consequences if there is an underlying medical issue, such as heart disease. Because Turner syndrome is linked to a slew of health difficulties, including heart disease, autoimmune illnesses, mental health issues, infertility, and hearing loss, pregnancy complications, apart from COVID-19, the demand for growth hormone treatments is rising.

Small for gestational age is the fastest-growing category, over this decade. This is attributed to the increasing awareness of this condition and its early diagnosis in children. Up to 15% of the children born around the world are small for gestational age, and many continue to show stunted growth even after the age of 3.

The report offers insights into the below-mentioned indications:

• Growth Hormone Deficiency
• Prader–Willi Syndrome
• Turner Syndrome (Largest Category)
• Small for Gestational Age (Fastest-Growing Category)
• Others

Distribution Channel Analysis

Hospital pharmacies account for the major market share, in 2024. This was due to the preference for synthetic or recombinant variants of this hormone and the ease with which it is available at hospital pharmacies. In addition, the rising awareness of growth hormone shortage, as well as the increasing volume of hospital visits for treatment, is predicted to propel the hospital pharmacy distribution channel sector forward.

Online pharmacies will have the highest CAGR during the forecast period, of 15.5%. This is attributed to the increasing popularity of e-commerce and growing trust in online pharmacies, which now ask for a signed doctor’s prescription before delivering medications. Online shopping has many well-known benefits, including promotional offers and discounts, detailed information on similar products of different brands, electronic payments, and doorstep delivery. Moreover, the COVID-19 pandemic has heightened people’s interest in avoiding the long queues at physical stores and shopping via their laptops and smartphones instead.

We have studied the following distribution channels:

• Hospital Pharmacy (Largest Category)
• Retail Pharmacy
• Online Pharmacy (Fastest-Growing Category)

Geographical Analysis

• North America has a market share of 45% in 2024, the largest around the world.
• The increase in the senior/aged population, as well as the high rates of Turner syndrome, short bowel syndrome, and Noonan syndrome, can all be related to the market's expansion in North America.
• Other factors include favorable reimbursement policies, significant government initiatives, awareness among the population, and established healthcare ecosystem in the country.
• Moreover, the region is home to several giants of the pharma and biopharma sectors, who are engaged in extensive research to create novel therapies. Additionally, the established healthcare infrastructure, major government initiatives, and expanding healthcare awareness are fueling the market in the region.
• The U.S. holds the largest share of the global human growth hormone market.
• The high expenditure on R&D on hormonal disorders and the country's high acceptance rate for technical breakthroughs lead to its strong market contribution.
• APAC is growing the fastest, with a CAGR of 16.0% over this decade.
• This is attributed to the high incidence of diseases for which human growth hormone is prescribed, rising awareness of these conditions and the role of HGH in their management, improving healthcare facilities with the support of the private sector and the government, and surging disposable income owing to an expanding middle class.
• For instance, the incidence of growth hormone deficiency among children of a low height in India is up to 70%.
• Similarly, 1 in 2,500 girls in the country is born with Turner syndrome.

The regional breakdown of the market is as follows:

• North America (Largest Regional Market)
  • U.S. (Larger Country Market)
  • Canada (Faster-Growing Market)
• Europe
  • U.K.
  • Germany (Largest Country Market)
  • France
  • Spain (Fastest-Growing Country Market)
  • Italy
  • Rest of Europe
• Asia-Pacific (APAC) (Fastest-Growing Regional Market)
  • China (Largest Country Market)
  • India (Fastest-Growing Country Market)
  • Japan
  • South Korea
  • Australia
  • Singapore
  • Rest of APAC
• Latin America (LATAM)
  • Brazil (Largest Country Market)
  • Mexico (Fastest-Growing Country Market)
  • Rest of LATAM
• Middle East and Africa (MEA)
  • Saudi Arabia (Largest Country Market)
  • South Africa
  • U.A.E. (Fastest-Growing Country Market)
  • Rest of MEA

Human Growth Hormone Market Share

The market is moderately consolidated with few market players holding significant market shares. Moreover, there have been several strategic developments for more-effective and long-lasting medications. The number of pipeline pharmaceuticals is growing due to the increasing R&D for viable therapies. Hence, many companies are working on creating new and advanced drugs to combat the competition in the market.

Human Growth Hormone Market Company News

• In November 2023, Lumos Pharma reported positive results from the phase 2 clinical trials of its oral human growth hormone pill.
• In June 2023 Pfizer Inc. announced the FDA approval for Ngenla, a treatment for growth hormone deficiency in children.